Santen Pharmaceutical Co., Ltd.

Other

Masaaki Kageyama

Shigeru Kinoshita

Kei Tashiro

Kazuhiko Mori

Takazumi Taniguchi

Masakazu Nakano

Tomohito Yagi

Jinzhong Zhang

Yoko Ikeda

For preventing or treating keratomycosis, a medicament containing rapamycin or a salt thereof as an active ingredient is used.

Fungal keratitis prophylactic or therapeutic agent

A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.

Method for determination of progression risk of glaucoma

Growing community of inventors

Emeryville, CA, United States of America

Masaaki Kageyama